Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company with two FDA-cleared products, has entered into a memorandum of understanding (“MoU”) with Ehave, Inc. (OTC: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors. The agreement calls for the two companies to work together to map brain response to psychedelics being administered as a treatment for chronic pain, depressions (both major and persistent), post-traumatic stress disorder, bipolar disorder, general anxiety, ADHD and schizophrenia. The two companies will also collaborate in the development of neural net algorithms for the mental-health sector. BRSF’s e-tattoo technology will be used to provide continuous monitoring in the studies. According to the announcement, the MoU calls for Ehave to integrate Brain Scientific’s NeuroCap and NeuroEEG to obtain data from patients in real time; Ehave may also use the two devices in clinical settings with Ehave’s partner healthcare providers in order to gather data about the electrophysiological changes in brain pre-, mid- and post-psychedelic drug administration. Initial plans indicate the collection research could start in Australia and then be implemented in other areas. The research and data will be jointly owned by both Ehave and Brain Scientific. “Our current EEG device is about the size of a stamp,” said Brain Scientific chairman Boris Goldstein in the press release. “By shrinking the technology, the system allows for continuous measurement during a person’s normal activities, while providing a non-intrusive way to monitor various disorders. We believe the future of EEG testing will be centered around the ability to gather more precise data through non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. By utilizing graphene, which has been called a ‘wonder material of the 21st century,’ Brain Scientific believes the size of the electrodes can be thinner than a human hair and will allow brain activity monitoring with minimal distraction from everyday life.”
To view the full article, visit https://ibn.fm/J4wAg
About Brain Scientific
Brain Scientific is a commercial-stage, health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information about this company, please visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.